Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.14969 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Yu Yan und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Southeast University Zhongda Hospital, Southeast University School of Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Aminobutyrates, Antihypertensive Agents, Biphenyl Compounds, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Young Scholars of Yangtze River Scholar Professor Program, Research Personnel Cultivation Programme of Zhongda Hospital Southeast University, Hypertension Research and Innovation Fund of Chinese Cardiovascular Association.
Abstract (Originalsprache)
To assess the effectiveness and safety of Sacubitril/Valsartan in reducing blood pressure in individuals with non‐dialysis‐dependent chronic kidney disease (NDD‐CKD) Stage 3–5 complicated by hypertension. This study was a multicenter retrospective analysis conducted from March 1, 2022 to March 31, 2024, involving adult patients with NDD‐CKD Stage 3–5 and hypertension, who received Sacubitril/Valsartan either as a monotherapy or in addition to current antihypertensive treatments that were insufficient. The main outcomes measured were blood pressure control, changes in blood pressure and laboratory parameters within 8 weeks post‐treatment initiation, and incidence of adverse events. The study included a total of 459 individuals with NDD‐CKD Stage 3–5 and hypertension. At the study endpoint, mean systolic blood pressure, diastolic blood pressure, and pulse pressure were markedly reduced compared to baseline (all p < 0.001). The average blood pressure reductions were 12.17 (4.66, 22.00), 6.00 (0.67, 12.66), and 6.67 (0.08, 14.00) mmHg, respectively. Throughout the study period, 96 patients (20.92%) with NDD‐CKD Stage 3–5 developed worsening renal function, 15 patients (3.27%) developed hyperkalemia, and 49 patients (10.68%) experienced symptomatic hypotension. Overall, there were no significant differences in the changes in serum creatinine, estimated glomerular filtration rate, and serum potassium before and after treatment ( p = 0.28, p = 0.91, p = 0.61, respectively). Sacubitril/Valsartan significantly lowers blood pressure in patients with NDD‐CKD Stage 3–5 complicated by hypertension, with good safety profiles. Trial Registration: ClinicalTrials.gov identifier: ChiCTR2400086079
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Southeast University Zhongda Hospital, Southeast University School of Medicine, Nanjing, China.
- Department of Pharmacy, Zhongda Hospital, Southeast University, Nanjing, China.
- Department of Nephrology, Taixing People's Hospital Affiliated to Yangzhou University, Taizhou, China.
- Department of Nephrology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
- Department of Nephrology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
- Department of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
ORCID-Profile: Bin Wang
Förderung
- Young Scholars of Yangtze River Scholar Professor Program
- Research Personnel Cultivation Programme of Zhongda Hospital Southeast University
- Hypertension Research and Innovation Fund of Chinese Cardiovascular Association
- Science and Technology Plan Special Fund (Key Research and Development Plan Social Development) of Jiangsu Province
- Wellcome Trust
- National Institute of Hospital Administration, NHC Research Program on high-quality development of hospital pharmacy
Zitieren
APA
Yan, Y., Li, X., Cao, J., Cao, J., Wang, Y., Wang, L., Yu, J., Chen, L., Yang, M., Huang, X., Shen, L., Ding, H., Li, M., Yin, D., Jiang, L., Tang, L., Jiang, Y., Hu, L., Si, J., …, & Wang, B. (2025). Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14969
Vancouver
Yan Y, Li X, Cao J, Cao J, Wang Y, Wang L, et al. Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.14969
BibTeX
@article{Yan2025,
author = {Yan, Yu and Li, Xiaomin and Cao, Juan and Cao, Jingyuan and Wang, Yao and Wang, Liang and Yu, Jirong and Chen, Lianhua and Yang, Min and Huang, Xinzhong and Shen, Lei and Ding, Hong and Li, Manzhi and Yin, Di and Jiang, Linglin and Tang, Liang and Jiang, Yujia and Hu, Ling and Si, Jiyi and Zhang, Hui and Cui, Liqin and Gu, Xiameng and Hu, Kun and Mu, Dongxing and Liu, Bicheng and Zhang, Xiaoliang and Sun, Dong and Wan, Xin and Wang, Bin},
title = {Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.14969}
}
EUVIMED